Galderma's CEO, Flemming Ørnskov, highlighted the company's strategic advantage stemming from the increased use of GLP-1 medications like Ozempic and Wegovy, which are leading to a growing patient base experiencing facial sagging due to weight loss.
Approximately 10% of U.S. adults are now using these drugs, creating a significant market opportunity for Galderma's aesthetic treatments, including fillers and Scuptra, designed to counteract this issue. The company reported nearly 25% year-on-year sales growth at constant currencies, with U.S. growth at an impressive 32%, outpacing the 19% growth seen in other markets.
Despite this positive outlook, Galderma's stock showed little movement in mid-morning trading, indicating that while the growth is promising, investors may be cautious about the sustainability of this trend